glp-1 agonists cardiovascular diseases The Biology of Glucagon-like Peptide-1 Cardiovascular and mortality outcomes with
Description
Like LIR, the race of patients involved in related clinical studies is relatively small
Chan DC, Watts GF, Ng TWK, Yamashita S, Barrett PHR
This might reduce healthcare costs, enhance patient well-being, and increase productivity [115]
However, this situation has changed dramatically with emerging evidence highlighting the metabolic benefits of dual GLP-1 receptor (GLP-1R) and GIPR agonists
